Precept Management’s Cue Biopharma CUE Stock Holding History

Precept Management’s Portfolio CUE Stock Details CUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-1,167	Closed	-$396K	–	59
2021 Q4	$396K	Hold	1,167	–	–	0.16%	44
2021 Q3	$510K	Hold	1,167	–	–	0.24%	74
2021 Q2	$408K	Hold	1,167	–	–	0.17%	64
2021 Q1	$427K	Sell	1,167 -3,833	-77%	-$1.58M	0.29%	45
2020 Q4	$1.88M	Hold	5,000	–	–	0.76%	29
2020 Q3	$2.26M	Sell	5,000 -1,417	-22%	-$816K	0.55%	40
2020 Q2	$4.72M	Sell	6,417 -583	-8%	-$422K	0.9%	38
2020 Q1	$2.98M	Buy	7,000 +1,333	+24%	+$646K	0.37%	40
2019 Q4	$2.7M	Buy	+5,667	New	+$1.78M	1.3%	22

Other funds holding CUE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

SPC

Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return

SMH

Sanders Morris Harris Houston, Texas $172M AUM 22.54% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Precept Management's CUE Position: Q1 2022 in Review

Precept Management sold out of Cue Biopharma (CUE) in Q1 2022, closing a stake of 1,167 shares — an estimated $396K sold.

Precept Management first reported a position in CUE in Q4 2019 and held it in 9 quarters. The position peaked at $4.72M in Q2 2020. 100 funds tracked by Wall St. Rank hold CUE as of Q1 2022.

Precept Management reported no remaining Cue Biopharma position as of Q1 2022 after selling out during the quarter.
Precept Management sold 1,167 Cue Biopharma shares in Q1 2022, an estimated $396K.
Precept Management first reported a position in Cue Biopharma in Q4 2019 and held it in 9 quarters.
Precept Management's Cue Biopharma position peaked at $4.72M in Q2 2020.
100 funds tracked by Wall St. Rank held Cue Biopharma as of Q1 2022.

Based on Precept Management's 13F filing for Q1 2022, filed 16 May 2022.